Literature DB >> 9784835

Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese.

K Akaba1, T Kimura, A Sasaki, S Tanabe, T Ikegami, M Hashimoto, H Umeda, H Yoshida, K Umetsu, H Chiba, I Yuasa, K Hayasaka.   

Abstract

We analyzed the bilirubin uridine diphosphate-glucuronosyltransferase (B-UGT) gene in 42 Japanese newborns with hyperbilirubinemia and determined that 21 infants were heterozygous while 3 was homozygous for Gly71Arg. Allele frequency of Gly71Arg was 0.32 in newborns with hyperbilirubinemia, which was significantly higher than 0.13 in healthy Japanese controls. This mutant allele is also prevalent among Korean and Chinese healthy controls with a frequency of 0.23 in both populations. However, this mutation was not detected in 50 healthy German controls. These data suggest that the high frequency of the Gly71Arg mutation of the B-UGT gene is associated with high incidence of neonatal hyperbilirubinemia in Japanese, Korean and Chinese populations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9784835     DOI: 10.1080/15216549800203512

Source DB:  PubMed          Journal:  Biochem Mol Biol Int        ISSN: 1039-9712


  44 in total

1.  High-throughput single-base mismatch detection for genotyping of UDP-glucuronosyltransferase (UGT1A1) with probe capture assay coupled with modified allele-specific primer extension reaction (MASPER).

Authors:  Osamu Kisaki; Seiji Kato; Kohei Shinohara; Hisahide Hiura; Tomohiro Samori; Hiroshi Sato
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 2.  Recent progress and clinical importance on pharmacogenetics in cancer therapy.

Authors:  Thomas I Peng Soh; Wei Peng Yong; Federico Innocenti
Journal:  Clin Chem Lab Med       Date:  2011-09-28       Impact factor: 3.694

Review 3.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

4.  Association of neonatal hyperbilirubinemia in breast-fed infants with UGT1A1 or SLCOs polymorphisms.

Authors:  Hiroko Sato; Toshihiko Uchida; Kentaro Toyota; Tomohiro Nakamura; Gen Tamiya; Miyako Kanno; Taeko Hashimoto; Masashi Watanabe; Kuraaki Aoki; Kiyoshi Hayasaka
Journal:  J Hum Genet       Date:  2014-11-13       Impact factor: 3.172

5.  Is there diversity among UGT1A1 polymorphism in Japan?

Authors:  Michiya Kobayashi; Shoichi Hazama; Kenichi Takahashi; Koji Oba; Naoko Okayama; Mitsuaki Nishioka; Yuji Hinoda; Masaaki Oka; Ken Okamoto; Hiromichi Maeda; Daisuke Nakamura; Junichi Sakamoto; Hideyuki Mishima
Journal:  World J Gastrointest Oncol       Date:  2012-07-15

6.  UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.

Authors:  Matthew P Goetz; Heidi A McKean; Joel M Reid; Sumithra J Mandrekar; Angelina D Tan; Mary A Kuffel; Stephanie L Safgren; Renee M McGovern; Richard M Goldberg; Axel A Grothey; Robert McWilliams; Charles Erlichman; Matthew M Ames
Journal:  Invest New Drugs       Date:  2013-10-10       Impact factor: 3.850

7.  Relation between Neonatal Icter and Gilbert Syndrome in Gloucose-6-Phosphate Dehydrogenase Deficient Subjects.

Authors:  Yadollah Zahedpasha; Mousa Ahmadpour; Haleh Akhavan Niaki; Ehsan Alaee
Journal:  J Clin Diagn Res       Date:  2014-03-15

8.  Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma.

Authors:  Steven G DuBois; Yael P Mosse; Elizabeth Fox; Rachel A Kudgus; Joel M Reid; Renee McGovern; Susan Groshen; Rochelle Bagatell; John M Maris; Clare J Twist; Kelly Goldsmith; M Meaghan Granger; Brian Weiss; Julie R Park; Margaret E Macy; Susan L Cohn; Greg Yanik; Lars M Wagner; Randall Hawkins; Jesse Courtier; Hollie Lai; Fariba Goodarzian; Hiroyuki Shimada; Najee Boucher; Scarlett Czarnecki; Chunqiao Luo; Denice Tsao-Wei; Katherine K Matthay; Araz Marachelian
Journal:  Clin Cancer Res       Date:  2018-08-09       Impact factor: 12.531

Review 9.  Pharmacogenetics: a tool for individualizing antineoplastic therapy.

Authors:  F Innocenti; L Iyer; M J Ratain
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

10.  Cord blood -fetoprotein as a predictive index for indirect hyperbilirubinemia in term neonates.

Authors:  Yadollah Zahedpasha; Mousa Ahmadpour-Kacho; Jafar Khalafi; Ali Bijani
Journal:  Caspian J Intern Med       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.